$2.10
0.94% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US35168W1036
Symbol
GUTS
Sector
Industry

Fractyl Health Stock price

$2.10
+0.73 53.28% 1M
+0.04 1.94% 6M
+0.04 1.94% YTD
-4.87 69.87% 1Y
-12.90 86.00% 3Y
-12.90 86.00% 5Y
-12.90 86.00% 10Y
NYSE, Closing price Tue, May 20 2025
-0.02 0.94%
ISIN
US35168W1036
Symbol
GUTS
Sector
Industry

Key metrics

Market capitalization $102.85m
Enterprise Value $122.17m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2,036.17
P/S ratio (TTM) P/S ratio 1,714.17
P/B ratio (TTM) P/B ratio 16.12
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-96.75m
Free Cash Flow (TTM) Free Cash Flow $-80.04m
Cash position $42.11m
EPS (TTM) EPS $-1.84
P/E forward negative
Short interest 10.94%
Show more

Is Fractyl Health a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Fractyl Health Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Fractyl Health forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Fractyl Health forecast:

Buy
100%

Financial data from Fractyl Health

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.06 0.06
-
100%
- Direct Costs 0.95 0.95
-
1,583%
-0.89 -0.89
-
-1,483%
- Selling and Administrative Expenses 19 19
-
32,450%
- Research and Development Expense 75 75
-
125,800%
-96 -96
-
-159,717%
- Depreciation and Amortization 0.91 0.91
-
1,517%
EBIT (Operating Income) EBIT -97 -97
-
-161,247%
Net Profit -89 -89
-
-148,517%

In millions USD.

Don't miss a Thing! We will send you all news about Fractyl Health directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fractyl Health Stock News

Neutral
GlobeNewsWire
one day ago
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1 TM gene therapy for patients with inadequately controlled T2D and obesity
Neutral
GlobeNewsWire
4 days ago
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs
Neutral
Business Wire
7 days ago
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health's Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platfor...
More Fractyl Health News

Company Profile

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Head office United States
CEO Harith Rajagopalan
Employees 107
Founded 2010
Website www.fractyl.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today